As a biomarker of neovascularization, ESM1 overexpression is also often used as an indicator of tumor progression and metastasis in certain malignances, such as glioblastoma, renal cell carcinoma, and non-small cell lung cancer [24–26, 36]. This evidence concerns the gene ESM1 and renal cell carcinoma.